Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
QLONILIK (CLONIDINE HYDROCHLORIDE) | LOERadar
Viewing data from:
Latest
2026-10-01
2026-09-01
2026-08-03
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
QLONILIK
NDA
Get alerts
CLONIDINE HYDROCHLORIDE | N221094 | CMP DEVELOPMENT LLC
1 strength
1 unique patent
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
1 unique patent by expiration date
Active (1)
Today
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
Today
12551466
Aug. 22, 2045
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 0.05MG/ML
RLD
1 patent
0 exclusivities
▴
SOLUTION;ORAL | Approved: Jul 29, 2026
Patents (1)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
12551466
Aug 22, 2045
—
—
Yes
U-4581
QLONILIK (CLONIDINE HYDROCHLORIDE) ORAL SOLUTION IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS
—